Valuation: Duality Biotherapeutics, Inc.

Market Cap 8.27B 9.71B 1.24B 1.11B 1.02B 929M 1.76B 116B 1.81B 12.24B 4.88B 62.15B 4.64B 4.54B 196B P/E 2026 *
-16.6x
P/E 2027 * -17.4x
Enterprise Value 7.94B 9.32B 1.19B 1.07B 982M 892M 1.69B 111B 1.74B 11.76B 4.69B 59.71B 4.46B 4.37B 189B EV / Sales 2026 *
5.87x
EV / Sales 2027 * 5.9x
Free-Float
80.28%
Yield 2026 *
-
Yield 2027 * -
10-26 Duality Biotherapeutics' Trial of Breast Cancer Drug Shows Improved Progression-Free Survival MT
10-26 Duality Biotherapeutics, Inc. Announces DYNASTY-Breast02 Global Phase 3 Clinical Trial Of Trastuzumab Pamirtecan Meets Primary Endpoint CI
10-19 Roche Partners With China's Hansoh in Deal That Could Top $15 Billion -- Update DJ
08-28 Duality Biotherapeutics, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
08-28 Duality Biotherapeutics Ties Up With Genentech to Develop Oncology Drugs MT
08-28 Duality Biotherapeutics, Inc. and Genentech, Inc. Enters into Global Collaboration and License Agreement to Develop Next-Generation ADCs Built on Duality Biotherapeutics, Inc.'s DUPAC Novel-Payload Platform CI
06-26 Duality Biotherapeutics, Inc. Announces Executive Changes, with Effect from June 26, 2026 CI
06-26 Duality Biotherapeutics, Inc. Announces Address Changes in Company?S Principal Place of Business in Hong Kong CI
06-26 Duality Biotherapeutics, Inc. commences an Equity Buyback Plan for 9,090,651 shares, representing 10% of its issued share capital, under the authorization approved on June 26, 2026. CI
06-25 Duality Biotherapeutics, Inc.'s Equity Buyback announced on May 26, 2026, has expired. CI
06-14 Duality Biotherapeutics Advances Shanghai STAR Market Listing Plan MT
05-26 Duality Biotherapeutics, Inc. commences an Equity Buyback Plan for 8,803,626 shares, representing 10% of its issued share capital, under the authorization approved on June 20, 2025. CI
05-19 Duality Biotherapeutics Launches $40 Million Stock Buyback; Shares Rise 3% MT
1 day-2.15%
1 week-3.85%
Current month+0.67%
1 month-41.59%
3 months-47.37%
6 months-59.81%
Current year-64.82%
1 week 103
Extreme 103
111.3
1 month 96
Extreme 96
187.4
Current year 96
Extreme 96
376.8
1 year 96
Extreme 96
376.8
3 years 96
Extreme 96
563.5
5 years 96
Extreme 96
563.5
10 years 96
Extreme 96
563.5
Manager TitleAgeSince
Chief Executive Officer 56 2019-07-02
Director of Finance/CFO 40 2026-03-22
Chief Tech/Sci/R&D Officer - 2025-04-06
Director TitleAgeSince
Chairman 56 2019-07-02
Director/Board Member 45 2026-03-22
Director/Board Member 40 2021-04-22
Date Insider Type Main position Quantity % Market Cap. Importance
11/5/26 Other 30,000 0.0333%
11/3/26 Other 30,000 0.0333%
11/2/26 Other 30,000 0.0333%
Change 5-day change 1-year change 3-year change Capi.($)
-2.24%-3.85%-64.49% - 1.2B
+1.44%+1.63%+48.17%+139.63% 1,258B
-0.47%+5.49%+49.03%+90.68% 679B
+0.20%+2.76%+34.37%+112.06% 518B
+0.17%+2.76%+44.07%+69.71% 390B
-0.48%+2.34%+70.66%+46.02% 367B
+0.76%+2.27%+31.59%+60.36% 307B
-1.29%+0.90%+5.77%+37.60% 293B
0.00%+0.86%+43.74%+74.04% 252B
+0.92%+2.03%+44.62%+125.07% 210B
Average -0.24%+0.85%+30.75%+83.91% 427B
Weighted average by Cap. -0.09%+1.17%+43.63%+96.83%

Financials

2026 *2027 *
Net sales 1.35B 1.59B 202M 181M 167M 152M 287M 18.97B 295M 2B 798M 10.17B 759M 743M 32.14B 1.35B 1.58B 202M 181M 167M 151M 287M 18.92B 295M 2B 796M 10.14B 757M 741M 32.05B
Net income -595M -699M -89.05M -79.86M -73.6M -66.84M -126M -8.35B -130M -881M -351M -4.47B -334M -327M -14.14B -600M -704M -89.72M -80.46M -74.15M -67.34M -127M -8.41B -131M -888M -354M -4.51B -337M -330M -14.25B
Net Debt -325M -382M -48.64M -43.62M -40.2M -36.51M -69.1M -4.56B -71.03M -481M -192M -2.44B -183M -179M -7.72B -307M -360M -45.92M -41.18M -37.95M -34.46M -65.23M -4.31B -67.05M -454M -181M -2.31B -172M -169M -7.29B
Projected Income Statement - Annual - Duality Biotherapeutics, Inc.
Logo Duality Biotherapeutics, Inc.
Duality Biotherapeutics Inc is an investment holding company principally engaged in clinical-stage biopharmaceuticals. The Company is dedicated to the development of antibody-drug conjugate (ADC) innovative therapeutics to treat cancer and autoimmune diseases. The Company's primary drug product candidates include DB-1303/BNT323, DB-1311/BNT324, DB-1310, DB-1305/BNT325, DB-1419 and DB-2304. The Company's products are mainly used for the targeted treatment of endometrial cancer (EC), breast cancer (BC), small-cell lung cancer (SCLC), castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), as well as head and neck squamous cell carcinoma (HNSCC). The Company principally conducts its businesses in domestic and overseas markets.
Employees
266
Date Price Change Volume
26-11-10 HK$104.80 -2.24% 97,500
26-11-10 HK$107.20 +2.88% 612,800
26-11-09 HK$104.20 -0.67% 940,140
26-11-06 HK$104.90 -5.67% 740,441
26-11-05 HK$111.20 +1.92% 1,608,600
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Duality Biotherapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
91.30CNY
Average target price
335.47CNY
Spread / Average Target
+267.42%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Duality Biotherapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. 9606 Stock